Thursday 1 September 2016, Amsterdam
A new report, now available on ASDReports, predicts that the Dermatological Drugs market will reach $39.25bn in 2026. This forecast and others appear in - Dermatological Drugs Market Forecast 2016-2026: Analysis of the Current Trends and Pipeline Opportunities in the Psoriasis, Skin Infection, Acne and Dermatitis Markets Including Current Products Such as Humira, Stelara, Enbrel, Remicade, Taltz, Cosentyx, Cubicin, Canesten, Epiduo, Bepanthen and Elocon with Assessment of Key Companies in the Dermatological Market Including Galderma, Johnson & Johnson, AbbVie, GSK, Pfizer and LEO Pharma published in July 2016.
The Dermatological Drugs Market Forecast 2016-2026: Analysis of the Current Trends and Pipeline Opportunities in the Psoriasis, Skin Infection, Acne and Dermatitis Markets Including Current Products Such as Humira, Stelara, Enbrel, Remicade, Taltz, Cosentyx, Cubicin, Canesten, Epiduo, Bepanthen and Elocon with Assessment of Key Companies in the Dermatological Market Including Galderma, Johnson & Johnson, AbbVie, GSK, Pfizer and LEO Pharma, report examines the current and future trends in the Dermatological Drugs Market with particular focus on recent pivotal developments in the sector including patent expiries, biosimilar approvals, patent invalidations, launch of new drugs and pipeline products. These developments in addition to changes in population demographics are changing the landscape of the dermatological drugs market.
Dermatological Drugs are used to treat and manage a wide variety of skin conditions from skin infections, dermatitis, psoriasis and acne. These dermatological diseases are very common, leading to a large patient population.
The driving force behind growth in this market is the high unmet clinical need for dermatological conditions, a healthy pipeline of development-stage products and new products launching onto the market as well as advances in drug delivery options. As the global population ages there is an increased demand for treatment of intermittent or long-standing conditions, in addition to an increased demand from populations in both emerging and developed economies to improve skin care and health. The highly fragmented dermatological drugs market is increasingly expected to innovate in order to meet these demands in a safe manner. Pipeline development of biologics and personalised dermatology treatments with more sophisticated technologies to improve drug delivery formulations, safety and efficacy are anticipated to be the next paradigm shift in the dermatological drugs market.
In this report, we examine in detail the factors which are driving growth in the Dermatological Drugs Market, the key companies currently operating in the market including their product pipelines. We also examine key national markets and discuss trends and variations within these markets, alongside an analysis of dermatological drugs.
The Dermatological conditions examined in this report are: Psoriasis, Skin Infections, Acne and Dermatitis. National Markets focused on are the US, China, Japan, EU5 (Germany, UK, Italy, France and Spain), Brazil, Russia and India.
Using both primary and secondary research, forecasts have been built for the major submarkets, leading products and leading national and regional markets, accompanied by text giving a thorough explanation of events thought to shape the market currently and in the future.
ASDReports.com Media contact: S. Koopman -
Marketing and Communications
ASDReports.com / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216 - E : email@example.com
back to News